Clinical trial
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With…
NCT00306813 · University of Wuerzburg, Other · Completed
Key facts
| NCT number | NCT00306813 |
|---|---|
| Title | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Multicenter Phase I/II Trial Evaluating the Safety and Efficacy of Lenalidomide (Revlimid, CC-5013) in Combination With Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | University of Wuerzburg, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Relapse, Refractory Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Revlimid |
| Enrollment | 53 |
| Start date | Sep 1, 2004 |
| Completion | Dec 1, 2008 |
| First posted | Mar 24, 2006 |
| Last update posted | Aug 4, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: